Gilead Sciences Inc (GILD) - Total Liabilities
Based on the latest financial reports, Gilead Sciences Inc (GILD) has total liabilities worth $36.41 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore GILD net assets growth trend to track the company's year-over-year net asset growth rate.
Gilead Sciences Inc - Total Liabilities Trend (1990–2024)
This chart illustrates how Gilead Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. See GILD free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Gilead Sciences Inc Competitors by Total Liabilities
The table below lists competitors of Gilead Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Foxconn Industrial Internet Co Ltd
SHG:601138
|
China | CN¥280.63 Billion |
|
Industria de Diseno Textil SA
MC:ITX
|
Spain | €18.04 Billion |
|
Marvell Technology Group Ltd
NASDAQ:MRVL
|
USA | $8.73 Billion |
|
Novo Nordisk A/S
CO:NOVO-B
|
Denmark | Dkr348.86 Billion |
|
Sumitomo Mitsui Financial Group Inc
NYSE:SMFG
|
USA | $313.93 Trillion |
|
Union Pacific Corporation
NYSE:UNP
|
USA | $50.23 Billion |
|
AT&T Inc.
NYSE:T
|
USA | $293.57 Billion |
|
Qualcomm Incorporated
NASDAQ:QCOM
|
USA | $29.86 Billion |
Liability Composition Analysis (1990–2024)
This chart breaks down Gilead Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GILD company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gilead Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gilead Sciences Inc (1990–2024)
The table below shows the annual total liabilities of Gilead Sciences Inc from 1990 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $39.75 Billion | +0.95% |
| 2023-12-31 | $39.38 Billion | -6.16% |
| 2022-12-31 | $41.96 Billion | -10.51% |
| 2021-12-31 | $46.89 Billion | -6.57% |
| 2020-12-31 | $50.19 Billion | +28.76% |
| 2019-12-31 | $38.98 Billion | -7.51% |
| 2018-12-31 | $42.14 Billion | -15.35% |
| 2017-12-31 | $49.78 Billion | +32.35% |
| 2016-12-31 | $37.61 Billion | +14.94% |
| 2015-12-31 | $32.73 Billion | +73.66% |
| 2014-12-31 | $18.84 Billion | +73.94% |
| 2013-12-31 | $10.83 Billion | -7.37% |
| 2012-12-31 | $11.70 Billion | +12.08% |
| 2011-12-31 | $10.44 Billion | +90.75% |
| 2010-12-31 | $5.47 Billion | +71.32% |
| 2009-12-31 | $3.19 Billion | +29.22% |
| 2008-12-31 | $2.47 Billion | +10.60% |
| 2007-12-31 | $2.23 Billion | +0.78% |
| 2006-12-31 | $2.22 Billion | +200.21% |
| 2005-12-31 | $738.54 Million | +159.05% |
| 2004-12-31 | $285.09 Million | -48.33% |
| 2003-12-31 | $551.75 Million | -23.03% |
| 2002-12-31 | $716.84 Million | +109.39% |
| 2001-12-31 | $342.35 Million | +4.70% |
| 2000-12-31 | $326.98 Million | +134.36% |
| 1999-12-31 | $139.52 Million | -9.46% |
| 1998-12-31 | $154.10 Million | +342.82% |
| 1997-12-31 | $34.80 Million | +83.16% |
| 1996-12-31 | $19.00 Million | +25.00% |
| 1995-12-31 | $15.20 Million | -6.75% |
| 1994-12-31 | $16.30 Million | +44.25% |
| 1993-12-31 | $11.30 Million | +52.70% |
| 1992-12-31 | $7.40 Million | +138.71% |
| 1991-12-31 | $3.10 Million | +34.78% |
| 1990-12-31 | $2.30 Million | -- |
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the t… Read more